Publications by authors named "Johanna Noel"
Article Synopsis
- Immunotherapy, particularly when combined with chemotherapy, has shown limited effectiveness against solid tumors due to factors like cancer cells promoting immune cell exhaustion through nutrient diversion in the tumor microenvironment (TME).
- The authors suggest using high doses of sodium citrate (SCT) alongside immune checkpoint inhibitors (ICIs) to inhibit cancer cell metabolism and enhance anti-tumor immune responses, as preclinical studies indicate SCT can reduce cancer growth and improve chemotherapy outcomes.
- SCT works by increasing available glucose for immune cells and lowering lactic acid levels in the TME, which may enhance T cell activity and repolarize macrophages, indicating its potential to significantly boost the effectiveness of current immunotherapies in clinical settings.
Concomitant direct oral anticoagulants (DOACs) and tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (anti-VEGF TKI) have been associated with a higher risk of bleeding. Nevertheless, concomitant administration seems frequent in clinical practice in patients with cancer-associated thrombosis and appears to be safe according to the retrospective study by Boileve A. et al.
View Article and Find Full Text PDFBackground: Nivolumab improved patients’ survival in metastatic renal cell carcinoma (mRCC). We aimed to evaluate resting energy expenditure (REE) (i.e.
View Article and Find Full Text PDFIntroduction: Cabazitaxel multiple rechallenges may be a treatment option in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had a good initial response to cabazitaxel and who are still fit to receive it. Our objective was to assess the efficacy and toxicity of multiple rechallenges.
Patients And Methods: We retrospectively identified 22 mCRPC patients previously treated with docetaxel and/or androgen receptor-targeted agents who received multiple cabazitaxel rechallenges in 9 French centers.
In the last few years, the standard of care for metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically with the emergence of the immune checkpoint inhibitors (ICI): anti-PD(L)-1 used as a monotherapy or as in combination either with an anti CTLA-4 or with an anti-angiogenic molecule (VEGFR tyrosine kinase inhibitor (TKI)). These combinations are now recommended in first line setting for mccRCC, according to the last European recommendations. In the face of these new therapeutic options, the question of selecting the best treatment arises as well as the optimal sequence.
View Article and Find Full Text PDF